New study: can a pill stop chemo nausea in advanced breast cancer?
NCT ID NCT07132749
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether the anti-nausea drug NEPA (netupitant/palonosetron) can prevent vomiting and nausea in people with advanced HER2-positive or HER2-low breast cancer who are receiving the drug T-DXd. It will follow 100 participants across multiple hospitals to see how well NEPA works during and after treatment. The goal is to improve comfort and quality of life during cancer therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NEPA (netupitant/palonosetron)
What this could lead to
If it works, this could show that NEPA effectively controls nausea and vomiting caused by T-DXd, improving quality of life for advanced breast cancer patients.
What could go wrong
This is an observational study, not a randomized trial, so results may be less definitive. It focuses on symptom control, not treating the cancer itself, and the benefit may vary among individuals.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Samsung Medical Center
Seoul, Gangnam-gu, 06355, South Korea